Pipeline Insight: Anxiety Disorders - A decade of declining revenues

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-03-29

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 (CAGR 200615 -6.0%). This will be primarily due to the launch of numerous generic anxiety drugs from 2006 onwards, which will offset the revenue growth derived from existing drugs seeking additional anxiety indications, and the launch of several novel anxiety drugs.


Scope

  • Detailed pipeline analysis for key products in development for GAD, SAD, OCD, PTSD, PMDD and panic disorder, plus drug sales forecasts to 2015
  • Overview of patient potential segmentation by indication and unmet needs in anxiety disorders across the US, Japan, France, Germany, Italy, Spain & UK
  • Benchmarking of key clinical and company attractiveness of late-phase pipeline products
  • Detailed clinical trial information and opinions from key thought leaders


    • Report Highlights
    To maximize drug revenues as a final step before generic incursion, a number of existing market players are seeking approvals in additional anxiety indications. However, sales of $1.6 billion in 2006 will decline over the long-term to $1.2 billion in 2015.

    Manufacturers with existing branded CNS drugs already approved for indications other than anxiety, are also seeking secondary indications in the anxiety market. Datamonitor forecasts that these drugs will enter the anxiety market from 2007 onwards, and will reach peak anxiety specific revenues of $413m in 2013.

    Several novel anxiety drugs will be launched over the forecast period from 2006 onwards, including Predix's PRX-00023 (oral non-azapirone 5-HT1A agonist) in Phase III for GAD, and Schering AG/Berlex's YAZ (low dose drospirenone/ethinyl estradiol) and Wyeth's Librel (low dose levonorgestrel/ethinyl estradiol), both in development for PMDD.


    Reasons to Purchase

  • Understand unmet needs in the anxiety market based on key opinion leader comments regarding both currently marketed and pipeline products
  • Benchmark key late-stage anxiety compounds against current market leaders
  • Assess the global sales forecasts of late-stage pipeline drugs for anxiety and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: anxiety anxiolytic panic stress disorder anxiety lyrica pipeline disorder disorders gabitril yaz drug gad market

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.